Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches
Nilanjan Adhikari, Sk. Abdul Amin, Prakruti Trivedi, et al.
European Journal of Medicinal Chemistry (2018) Vol. 157, pp. 1127-1142
Closed Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Why 90% of clinical drug development fails and how to improve it?
Duxin Sun, Wei Gao, Hongxiang Hu, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 7, pp. 3049-3062
Open Access | Times Cited: 887
Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview
Subha Mondal, Nilanjan Adhikari, Suvankar Banerjee, et al.
European Journal of Medicinal Chemistry (2020) Vol. 194, pp. 112260-112260
Closed Access | Times Cited: 425
HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya, Sk. Abdul Amin, Nilanjan Adhikari, et al.
Pharmacological Research (2020) Vol. 163, pp. 105274-105274
Closed Access | Times Cited: 187
Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors
Goverdhan Lanka, Darakhshan Begum, Suvankar Banerjee, et al.
Computers in Biology and Medicine (2023) Vol. 166, pp. 107481-107481
Closed Access | Times Cited: 59
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Rajat Sarkar, Suvankar Banerjee, Sk. Abdul Amin, et al.
European Journal of Medicinal Chemistry (2020) Vol. 192, pp. 112171-112171
Closed Access | Times Cited: 100
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Suvankar Banerjee, Nilanjan Adhikari, Sk. Abdul Amin, et al.
European Journal of Medicinal Chemistry (2018) Vol. 164, pp. 214-240
Closed Access | Times Cited: 99
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Mengjiao Zhou, Minjian Yuan, Meng Zhang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113825-113825
Open Access | Times Cited: 58
The emerging roles of HDACs and their therapeutic implications in cancer
Rihan Hai, Deyi Yang, Feifei Zheng, et al.
European Journal of Pharmacology (2022) Vol. 931, pp. 175216-175216
Closed Access | Times Cited: 49
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer
Sravani Pulya, Ambati Himaja, Milan Paul, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12033-12058
Closed Access | Times Cited: 30
Ketogenic Diet Elicits Antitumor Properties through Inducing Oxidative Stress, Inhibiting MMP-9 Expression, and Rebalancing M1/M2 Tumor-Associated Macrophage Phenotype in a Mouse Model of Colon Cancer
Ning Zhang, Chunhong Liu, Li Jin, et al.
Journal of Agricultural and Food Chemistry (2020) Vol. 68, Iss. 40, pp. 11182-11196
Closed Access | Times Cited: 63
Ferrocenes in medicinal chemistry; a personal perspective
Supojjanee Sansook, Storm Hassell‐Hart, Cory A. Ocasio, et al.
Journal of Organometallic Chemistry (2019) Vol. 905, pp. 121017-121017
Open Access | Times Cited: 59
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
Ping Gong, Yuetong Wang, Yongkui Jing
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 7, pp. 1601-1601
Open Access | Times Cited: 56
Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
Meiling Huang, Jian Zhang, Changjiao Yan, et al.
Bioorganic Chemistry (2019) Vol. 91, pp. 103184-103184
Closed Access | Times Cited: 55
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari, Tarun Jha, Balaram Ghosh
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8827-8869
Closed Access | Times Cited: 46
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma
Jennifer E. Amengual, Jennifer Kimberly Lue, Helen Ma, et al.
The Oncologist (2021) Vol. 26, Iss. 3, pp. 184-e366
Open Access | Times Cited: 41
KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progression
Haoran Wei, Wenhao Ma, Xiaofei Lü, et al.
Cancer Communications (2021) Vol. 41, Iss. 9, pp. 904-920
Open Access | Times Cited: 39
Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer
Sravani Pulya, Tarun Patel, Milan Paul, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114470-114470
Closed Access | Times Cited: 28
The role of protein acetylation in carcinogenesis and targeted drug discovery
Jingru Yang, Cong Song, Xianquan Zhan
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 28
Recent development of selective inhibitors targeting the HDAC6 as anti-cancer drugs: Structure, function and design
Jie Peng, Fei Xie, Pengxia Qin, et al.
Bioorganic Chemistry (2023) Vol. 138, pp. 106622-106622
Open Access | Times Cited: 15
Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity
Prakruti Trivedi, Nilanjan Adhikari, Sk. Abdul Amin, et al.
European Journal of Pharmaceutical Sciences (2019) Vol. 138, pp. 105046-105046
Closed Access | Times Cited: 38
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Joshua P. Smalley, Shaun M. Cowley, James T. Hodgkinson
Molecules (2020) Vol. 25, Iss. 19, pp. 4394-4394
Open Access | Times Cited: 38
Harnessing photocatalytic and electrochemical approaches for C–H bond trifluoromethylation and fluoroalkylation
Ranjay Shaw, Naveen Sihag, Hemaang Bhartiya, et al.
Organic Chemistry Frontiers (2023) Vol. 11, Iss. 3, pp. 954-1014
Closed Access | Times Cited: 12
Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides
Sk. Abdul Amin, Nilanjan Adhikari, Sonali Kotagiri, et al.
European Journal of Medicinal Chemistry (2019) Vol. 166, pp. 369-380
Closed Access | Times Cited: 34
krCRISPR: an easy and efficient strategy for generating conditional knockout of essential genes in cells
Bei Wang, Zishi Wang, Daqi Wang, et al.
Journal of Biological Engineering (2019) Vol. 13, Iss. 1
Open Access | Times Cited: 34
Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors
Ganesh Routholla, Sravani Pulya, Tarun Patel, et al.
Bioorganic Chemistry (2021) Vol. 114, pp. 105050-105050
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top